Vitiligo

  • José Johani García Gómez Universidad de Antioquia
  • Rafael Falabella Universidad del Valle
  • Gloria Sanclemente Mesa Universidad de Antioquia
Palabras clave: vitiligo, etiopatogenia, manifestaciones clínicas, terapia

Resumen

El vitiligo es una enfermedad caracterizada por la pérdida de melanocitos epidérmicos; es una de las formas más comunes de leucodermia y se ha estimado que más de la mitad de quienes la padecen se afectan antes de la edad de veinte años. En los últimos años se han propuesto múltiples teorías acerca de su patogénesis; no obstante, su tratamiento sigue siendo un reto. En este artículo de revisión se describen algunas de las diferentes hipótesis acerca de la etiología del vitiligo, sus manifestaciones clínicas y las diversas terapias utilizadas para ella en la actualidad.

Biografía del autor/a

José Johani García Gómez, Universidad de Antioquia

Dermatólogo, Umdad de Fototerapia, IPS-Universidad de Antioquia, Medellín.

Rafael Falabella, Universidad del Valle

Docente Dermatología, Jefe Sección de Dermatología, Departamento de Medicina Interna, Universidad del Valle, Cali

Gloria Sanclemente Mesa, Universidad de Antioquia

Dermatóloga, MSc, Docente Sección de Dermatología, Departamento de Medicina Interna, Facultad de
Medicina, Universidad de Antioquia, Medellín.

Referencias bibliográficas

1. Roelandts R. Photo(chemo)therapy for vitiligo. Photo-dermatol, Photoimmunol, Photomed 2003; 19:1-4.
https://doi.org/10.1034/j.1600-0781.2003.00003.x

2. Sanclemente G, Mahecha M, Guzmán C. Enfermeda-des de la piel más frecuentes en la consulta externa dermatológica del Hospital Universitario San Vicente de Paúl y del Hospital Infantil. Acta Med Colomb 2001; 26: 240-244.

3. Njoo M, Bos J, Weesterhof W. Treatment of generali-zed vitiligo in children with narrow-band (TL-01) UVB radiation therapy. J Am Acad Dermatol 2000; 42: 245- 253.
https://doi.org/10.1016/S0190-9622(00)90133-6

4. Gauthier Y, Andre MC, Tae"ib A. A critica! appraisal of vitiligo etiologic teories. Is melanocyte loss a melanoci-torrhagia? Pigment Cell Res 2003; 16: 322-332.
https://doi.org/10.1034/j.1600-0749.2003.00070.x

5. Kovacs S. Vitiligo. J Am Acad Dermatol 1998; 38: 647-666.
https://doi.org/10.1016/S0190-9622(98)70194-X

6. Halder RM, Notheeti PK. Ethnic disorders overview. J Am Acad Dermatol 2003; 48: 143-148.
https://doi.org/10.1067/mjd.2003.274

7. Kent G, AI-Abadie M. Factors affecting responses on dermatology lite quality index items among vitiligo su-fferers. Clin Exp Dermatol 1996; 21 :330-333.
https://doi.org/10.1111/j.1365-2230.1996.tb00116.x

8. Jablonski NG, Chaplin G. The evolution of human skin coloration. J Hum Evol. 2000; 39:57-106.
https://doi.org/10.1006/jhev.2000.0403

9. Njoo MD, Westerhof W. Vitiligo: pathogenesis and treat- ment. Am J Clin Dermatol 2001; 2: 167-181.
https://doi.org/10.2165/00128071-200102030-00006

10. Kemp EH, Waterman EA, Gawkrodger DJ, Watson PF, Weetman AP. Molecular mapping of epitopes on mela- nocyte-specific protein Pmel17 which are recognized by autoantibodies in patients with vitiligo. Clin Exp lm-munol 2001; 124:509-515.
https://doi.org/10.1046/j.1365-2249.2001.01516.x

11. Kemp EH, Waterman EA, Gawkrodger DJ, Watson PF, Weetman AP. Autoantibodies to tyrosinase-related pro- tein-1 detected in the sera of vitiligo patients using a quantitative radiobinding assay. Br J Dermatol 1998; 139:798-805.
https://doi.org/10.1046/j.1365-2133.1998.02503.x

12. Kemp EH, Gawkrodger DJ, Watson PF, Weetman AP. Autoantibodies to human melanocyte-specific protein pmel17 in the sera of vitiligo patients: a sensitive and quantitative radioimmunoassay (RIA). Clin Exp lmmu- nol 1998; 114:333-338.
https://doi.org/10.1046/j.1365-2249.1998.00746.x

13. Ongenae K, Van Geel N, Naeyaert JM. Evidence for an autoimmune pathogenesis of vitiligo. Pigment Cell Res 2003; 16: 90-1 OO.
https://doi.org/10.1034/j.1600-0749.2003.00023.x

14. Grimes PE, Morris R, Avaniss-Aghajani E, Soriano T, Meraz M, Metzger A. Topical tacrolimus therapy for vi- tiligo: therapeutic responses and skin messenger RNA expression of proinflammatory cytokines. J Am Acad Dermatol 2004; 51 :52-61.
https://doi.org/10.1016/j.jaad.2003.12.031

15. Cucchi ML, Frattini P, Santagostino G, Orecchia G. Hig- her plasma catecholamine and metabolite levels in the early phase of nonsegmental vitiligo. Pigment Cell Res 2000;13:28-32.
https://doi.org/10.1034/j.1600-0749.2000.130106.x

16. Falabella R, Barona M, Echeverri 1, Alzate A. Substan- ce P may play a part during depigmentation in vitiligo. A pilo! study. J Eur Acad Dermatol Venerol 2003; 17:355- 356.
https://doi.org/10.1046/j.1468-3083.2003.00792_6.x

17. Casp C, She JX, McCormack W. Genetic association of the catalase gen (CAT) with vitiligo susceptibility. Pig- ment Cell Res 2002; 15: 62-66.
https://doi.org/10.1034/j.1600-0749.2002.00057.x

18. Schallreuter K, Moore J, Wood J, Beazly W et al. In vivo and in vitro evidence for hydrogen peroxide (H202) ac- cumulation in the epidermis of patients with vitiligo and its successful removal by an UVB-activated pseudoca-talase. J lnvest Dermatol Symp Proc 1999; 4:91-96.
https://doi.org/10.1038/sj.jidsp.5640189

19. Ledo E, Ledo A. Phototherapy, photochemotherapy, and photodynamic therapy: unapproved uses or indicatio-ns. Clin Dermatol 2000; 18:77-86.
https://doi.org/10.1016/S0738-081X(99)00096-6

20. Shaffrali FCG, Gawkrodger J. Management of vitiligo. Clin Exp Dermatol 2000; 25:575-579.
https://doi.org/10.1046/j.1365-2230.2000.00709.x

21. Westerhof W, Nieuweboer-Krobotova L, Mulder P, Gla-zenburg E. Left-right comparison study of the combi- nation of fluticasone propionate and UV-A vs either flu-ticasone propionate or UV-A alone for the long-term treatment of vitiligo. Arch Dermatol 1999; 135:1061- 1066.
https://doi.org/10.1001/archderm.135.9.1061

22. Schallreuter K, Moore J, Wood J, Beazly W, et al. Epi- dermal H202 accumulation alters tetrahydrobiopterin (6BH4) recycling in vitiligo: identification of a general mechanism in regulation of all 6BH4-dependent pro-cesses? J lnvest Dermatol 2001; 116:167-174.
https://doi.org/10.1046/j.1523-1747.2001.00220.x

23. Schallreuter K. Effectiveness of pseudocatalase formu- lations in vitiligo. Clin Exp Dermatol 2003; 28: 561-563.
https://doi.org/10.1046/j.1365-2230.2003.01351_1.x

24. Schallreuter K, Moore J, Behrens-Williams S, et al. Ra- pid initiation of repigmentation in vitiligo with Dead Sea climatotherapy in combination with pseudocatalase (PS- KUS). lnt J Dermatol 2002; 41: 482-487.
https://doi.org/10.1046/j.1365-4362.2002.01463.x

25. Lee D, Lazova R, Bolognia JL A figurate papulosqua-mous variant of inflammatory vitiligo. Derrnatology 2000; 200:270-274.
https://doi.org/10.1159/000018374

26. Kóse O, Gür AR, Kurumlu Z, Erol E. Calcipotriol oint- ment versus cloetasol ointment in localized vitiligo: an open, comparative trial. lnt J Dermatol 2002; 41:612- 621.
https://doi.org/10.1046/j.1365-4362.2002.01486_3.x

27. Vázquez-López F, López-Escobar M, Pérez-Oliva N. Calcipotriene and vitiligo. Arch Dermatol 2003; 139:1656.
https://doi.org/10.1001/archderm.139.12.1656

28. Lepe V, Moneada B, Castanedo-Cazares J, et al. Ado- uble-blind randomized trial of O, 1 % tacrolimus vs 0,05%clobetasol for the treatment of childhood vitiligo. Arch Dermatol 2003; 139:581-585.
https://doi.org/10.1001/archderm.139.5.581

29. Plettenberg H, Assmann T, Ruzicka T. Childhood vitili- go and tacrolimus. lmmunomodulating treatment for an autoimmune disease. Arch Dermatol 2003; 139: 651- 654.
https://doi.org/10.1001/archderm.139.5.651

30. Westerhof W, Nieuweboer-Krobotova L. Treatment of vitiligo with UV-B radiation vs. topical psoralen plus UV-A. Arch Dermatol 1997; 133:1525-1528.
https://doi.org/10.1001/archderm.1997.03890480045006

31. Tjioe M, Gerritsen M, Juhlin L, Van der Kerkhof P. Treat- ment of vitiligo vulgaris with narrow-band UV-B (311 nm) for one year and the effect of addition of folie acid and vitamin B12. Acta Derrn Venereol 2002; 82:369-372.
https://doi.org/10.1080/000155502320624113

32. Njoo M, Bos J, Westerhof W. Treatment of generalized vitiligo in _children with narrow-band (TL -01) UVB ra- diation therapy. J Am Acad Derrnatol 2000; 42: 245- 253.
https://doi.org/10.1016/S0190-9622(00)90133-6

33. Scherschun L, Kim J, Lim H. Narrow band ultraviolet B is an useful and well-tolerated treatment for vitiligo. J AmAcad Dermatol 2001; 44: 999-1003.
https://doi.org/10.1067/mjd.2001.114752

34. Natta R, Somsak T, Wisuttidda T. Narrow band ultra-violet B radiation therapy for recalcitrant vitiligo in Asians. J Am Acad Dermatol 2003; 49: 473-476.
https://doi.org/10.1067/S0190-9622(03)01484-1

35. Yashar S, Gielczyk R, Scherschun L, Lim H. Narrow band ultraviolet B treatment for vitiligo, pruritus and in- flammatory dermatoses. Photodermatol, Photoimmu- nol, Photomed 2003; 19:164-168.
https://doi.org/10.1034/j.1600-0781.2003.00039.x

36. Parsad D, Pandhi R, Juneja A. Effectiveness of oral Ginkgo biloba in treating limited, slowly spreading vitili-go. Clin Exp Dermatol 2003; 28: 285-287.
https://doi.org/10.1046/j.1365-2230.2003.01207.x

37. Boisseau - Garsaud A, Garsaud P, Lejoly - Boisseau H, et al. lncrease in total blood antioxidant status and se- lenium levels in black patients with active vitiligo. lnt J Dermatol 2002; 41: 640-642.
https://doi.org/10.1046/j.1365-4362.2002.01472.x

38. de Leeuw J, van der Beek N, Maierhofer G, Neuge- bauer WD. A case study to evaluate the treatment of vitiligo with khellin encapsulated in L-phenylalanin sta- bilized phosphatidylcholine liposomes in combination with ultraviolet light therapy. Eur J Dermatol. 2003; 13:474-477.

39. Mutalik S, Ginzburg A. Surgical management of stable vitiligo: a review with personal experience. Dermatol Surg 2000; 26: 248-254.
https://doi.org/10.1046/j.1524-4725.2000.09182.x

40. Fallabella R. Surgical treatment of vitiligo, why, when and how. J Eur Acad Dermatol 2003 17:518-520.
https://doi.org/10.1046/j.1468-3083.2003.00718.x

41. Falabella R. Surgical therapies for vitiligo and other leu- kodermas, part 1: minigrafting and suction epidermal grafting. Derrnatol Ther 2001, 14:7-14.
https://doi.org/10.1046/j.1529-8019.2001.014001007.x

42. Falabella R, Arrunategui A, Barona MI, Alzate A. The minigrafting test for vitiligo: detection of stable lesions for melanocyte transplantation. J Am Acad Dermatol 1995; 32: 228-232.
https://doi.org/10.1016/0190-9622(95)90131-0

43. Mulekar SV. Long-terrn follow-up study of segmenta!and focal vitiligo treated by autologous, noncultured me- lanocyte-keratinocyte cell transplantation. Arch Derrna- tol 2004;140:1211-1215.
https://doi.org/10.1001/archderm.140.10.1211
Cómo citar
1.
García Gómez JJ, Falabella R, Sanclemente Mesa G. Vitiligo. rev. asoc. colomb. dermatol. cir. dematol. [Internet]. 1 de diciembre de 2004 [citado 5 de octubre de 2022];12(4):12-. Disponible en: https://revista.asocolderma.org.co/index.php/asocolderma/article/view/600

Descargas

La descarga de datos todavía no está disponible.
Publicado
2004-12-01
Sección
Sin sección en el original

Artículos más leídos del mismo autor/a